AbCellera Biologics (ABCL) Share-based Compensation (2020 - 2026)

AbCellera Biologics has reported Share-based Compensation for 7 years, with the latest figure at $12.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 18.75% year-over-year to $12.0 million; the trailing twelve-month figure through Mar 2026 stood at $53.0 million (down 18.38% YoY), and the FY2025 full-year result was $55.8 million, down 17.44% from the prior year.
• Share-based Compensation for Q1 2026 stood at $12.0 million, down from $12.9 million in the prior quarter.
• The five-year high for Share-based Compensation was $17.8 million in Q2 2024, with the low at $11.8 million in Q3 2022.
• Historically, Share-based Compensation has averaged $14.6 million across 5 years, with a median of $14.8 million in 2025.
• Annual changes were most pronounced in 2022 — Share-based Compensation surged 126.48% — and 2025, when it retreated 20.1%.
• AbCellera Biologics' Share-based Compensation stood at $13.3 million in 2022, then advanced by 23.46% to $16.4 million in 2023, then decreased by 7.43% to $15.2 million in 2024, then fell by 15.25% to $12.9 million in 2025, then dropped by 6.9% to $12.0 million in 2026.
• The last three Share-based Compensation figures came in at $12.0 million (Q1 2026), $12.9 million (Q4 2025), and $13.9 million (Q3 2025), per Business Quant data.